



Our Core Strengths Create the Foundation for Diversified, Durable Growth and Dependable Performance.

As a global medical technology innovator leading the way in women's health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are rooted in *The Science of Sure*®, our promise to deliver world-class certainty, precision and quality to healthcare providers and their patients.

DIVISION	CORE PRODUCTS	EXPANDING PORTFOLIO
DIAGNOSTIC SOLUTIONS	<p>Panther System® • Aptima® STI Assays • ThinPrep® Pap Test and Cytology Instruments</p>	<p>Aptima BV and CV/TV Assays</p> <ul style="list-style-type: none"> Nucleic acid amplification tests. Used to detect the three leading causes of vaginosis and vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis. <p>Breast Cancer Index Test™</p> <ul style="list-style-type: none"> Used to predict which breast cancer patients are likely to benefit from extended endocrine therapy. The only test of its kind recognized by key medical societies. Reimbursed by Medicare and key insurance providers. <p>Panther Fusion® Assays</p> <ul style="list-style-type: none"> Expands the molecular assay menu running efficiently on Panther Scalable Solutions. Hologic's syndromic solutions (Respiratory & GI assays) enable testing tailored to the individual, reducing unnecessary use of resources and time.
BREAST & SKELETAL HEALTH SOLUTIONS	<p>3Dimensions® • Affirm® Breast Biopsy Systems • Trident® Specimen Radiography System • Localizer™ Wire-free Guidance System</p>	<p>Genius AI™</p> <ul style="list-style-type: none"> Supports radiologists in improving accuracy and consistency of breast cancer detection. Designed to maximize effectiveness of 3D mammography. Software is fully integrated on 3Dimensions systems. <p>Interventional Needles</p> <ul style="list-style-type: none"> Portfolio of tissue-acquisition needles that function with stereotactic and ultrasound systems. Provide ease of use with world-class accuracy, consistency and efficiency.
GYN SURGICAL SOLUTIONS	<p>NovaSure® • MyoSure®</p>	<p>Fluent® Pro</p> <ul style="list-style-type: none"> Fluid management system for hysteroscopies. Provides simplified set-up and operation. Advanced technology designed to increase clinical confidence. <p>Sonata System</p> <ul style="list-style-type: none"> Transcervical fibroid ablation for treatment of symptomatic uterine fibroids. Delivers a breakthrough alternative to hysterectomy and myomectomy. Incisionless, transcervical delivery avoids the peritoneal cavity, allowing faster recovery times. <p>CoolSeal® Portfolio</p> <ul style="list-style-type: none"> Gold-standard efficacy of advanced bipolar RF vessel sealing technology. Versatile applications for pediatric and gynecologic procedures. Devices cut and dissect with precision in tight spaces and with minimal thermal footprint. <p>Omni® Hysteroscopes</p> <ul style="list-style-type: none"> Three interchangeable sheaths to enable flexible diagnosis and treatment with a single instrument. Provide a clear view of the cervical canal and uterine cavity.

Growing Performance, Growing Impact

HOLOGIC®

Revenue Highlights 1Q26

Revenue (\$M)	1Q26	Reported Delta vs. 1Q25	CC Delta vs. 1Q25
Diagnostics	\$464.4	-1.3%	-2.7%
Organic Diagnostics ex. COVID-19 ³	\$428.0	1.2%	-0.3%
Organic Molecular Diag. ex. COVID-19 ³	\$301.2	1.2%	0.0%
Breast Health	\$375.9	1.8%	0.8%
Organic Breast Health ²	\$375.8	1.9%	0.8%
GYN Surgical	\$180.8	8.7%	7.5%
Organic Surgical ²	\$171.7	3.2%	2.0%
Skeletal Health	\$26.7	69.0%	65.9%
Total Revenue	\$1,047.8	2.5%	1.3%
Organic Revenue ²	\$1,030.2	1.3%	-0.0%
Organic ex. COVID-19 ³	\$1,002.2	2.9%	1.6%
US Revenue	\$773.5	2.0%	
International Revenue	\$274.3	4.0%	-1.0%

Financial Overview 1Q26

Non-GAAP in Millions ex. EPS	1Q26	Delta vs. 1Q25
Revenue (\$M)	\$1,047.8	2.5%
Organic Revenue ²	\$1,030.2	1.3%
Organic ex COVID-19 ³	\$1,002.2	2.9%
Gross Margin Operating	60.1%	(150 bps)
Expenses Operating	\$326.6	-0.7%
Margin	29.0%	(40 bps)
Net Margin	22.5%	(90 bps)
Diluted EPS	\$1.04	1.0%
Adjusted EBITDA	\$330.4	1.3%

Financial Results


Net Debt & Leverage Ratio¹




Revenue & CC Growth Rates



Non-GAAP EPS & Growth Rates




2025 Divisional Revenue by Geography



Adjusted Operating Cash Flow⁴



ROIC



1. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA. 2. Organic revenue excludes the acquired Gynesonics business, and the divested Blood and SSI businesses. 3. Total organic revenue excluding COVID-19.

4. Operating cash flow adjusted for one-time tax and litigation items.

© 2024 Hologic Inc. All rights reserved. Hologic and The Science of Sure are trademarks of Hologic Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions, Acessa, Affirm, Aptima, Breast Cancer Index, Brevera, CoolSeal, Dimensions, Fluent, LOCALizer, MyoSure, NovaSure, Novodiag, Panther, Panther Fusion, ThinPrep. All other trademarks, registered trademarks and product names are the property of their respective owners.

Purpose-Driven Company



Through our substantial commitment to R&D innovation, we generate strong financial results, allowing us to invest in groundbreaking health initiatives for women and underserved communities.

Global Health:

- Hologic Global Women's Health Index represents the views of 94% of the world's women and girls aged 15 or older.
- Global Access Initiative provides cost-effective, high-quality diagnostic testing across sub-Saharan Africa.
- Philanthropic donations aid charitable groups focused on women's health, STEM education and social equality.



Global Reach:

Locations in 36+ countries with direct staff and a market presence in more than 100 countries.



Global Headquarters:

Marlborough, Massachusetts, USA.

Hologic.com